**Effectiveness of analgesic ear drops as add-on treatment to oral analgesics in children with acute otitis media: study protocol of the OPTIMA pragmatic randomised controlled trial**  
Joline LH de Sévaux1,Roger AMJ Damoiseaux1, Saskia Hullegie1, Elisabeth AM Sanders2,3, G Ardine de Wit1,4, Nicolaas P A Zuithoff1, Lucy Yardley5,6, Sibyl Anthierens7, Paul Little8, Alastair D Hay9, Anne GM Schilder1,10,11, Roderick P Venekamp1  
  
1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

2 Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

3 Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands

4 Centre for Nutrition, Prevention and Healthcare, National Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands

5School of Psychological Science, Faculty of Life Sciences, University of Bristol, Bristol, United Kingdom

6 School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom  
7 Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

8 Primary Care Research Centre, Primary Care Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Aldermoor Health CentreSouthampton, United Kingdom

9 Centre for Academic Primary Care, Bristol medical School: Population Health Sciences, University of Bristol, Bristol, United Kingdom  
10 National Institute for Health Research University College London Hospitals Biomedical Research Centre

11 evidENT, Ear Institute, University College London, London, United Kingdom

**Corresponding author**

Joline LH de Sévaux  
Julius Center for Health Sciences and Primary Care  
University Medical Center Utrecht  
Str. 6.131, P.O. Box 85500, 3508 GA Utrecht, the Netherlands  
Tel: +31 6 25 71 00 99  
Email: j.l.h.desevaux-2@umcutrecht.nl

**ABSTRACT  
Introduction**Ear pain is the most prominent symptom of childhood acute otitis media (AOM). To control the pain and reduce reliance on antibiotics, evidence of effectiveness for alternative interventions is urgently needed. This trial aims to investigate whether analgesic ear drops added to usual care provide superior ear pain relief over usual care alone in children presenting to primary care with AOM.

**Methods and analysis**This is a pragmatic, two arm, individually randomised, open, superiority trial with cost-effectiveness analysis and nested mixed-methods process evaluation in general practices in the Netherlands. We aim to recruit 300 children aged 1-6 years with a general practitioner (GP)-diagnosis of AOM and ear pain. Children will be randomly allocated (ratio 1:1) to either 1) lidocaine hydrochloride 5mg/g ear drops (Otalgan) 1-2 drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics) or 2) usual care. Parents will complete a symptom diary for 4 weeks as well as generic and disease-specific quality of life questionnaires at baseline and 4 weeks. The primary outcome is the parent-reported ear pain score (0-10) over the first 3 days. Secondary outcomes include proportion of children consuming antibiotics, oral analgesic use and overall symptom burden in the first 7 days; number of days with ear pain, number of GP reconsultations and subsequent antibiotic prescribing, adverse events, complications of AOM and cost-effectiveness during 4-week follow-up; generic and disease-specific quality of life at 4 weeks; parents’ and GPs’ views and experiences with treatment acceptability, usability and satisfaction.

**Ethics and dissemination**The Medical Research Ethics Committee Utrecht, the Netherlands, has approved the protocol (21-447/G-D). All parents/guardians of participants will provide written informed consent. Study results will be submitted for publication in peer reviewed medical journals and presented at relevant (inter)national scientific meetings.   
**Trial registration:** The Netherlands Trial Register; NL9500. Date of registration: 28 May 2021. At the time of publication of the study protocol paper, we were unable to make any amendments to the trial registration record in the Netherlands Trial Register. The addition of a data sharing plan was required to adhere to the International Committee of Medical Journal Editors (ICMJE) guidelines. The trial was therefore re-registered in ClinicalTrials.gov (NCT05651633; date of registration: 15 December 2022). This second registration is for modification purposes only and the NTR record (NL9500) should be regarded as the primary trial registration. **Word count:** 3586 (excluding title page, abstract, references, figures and boxes).

**Keywords:** acute otitis media; children, primary care; analgesic ear drops; randomised controlled trial.

**ARTICLE SUMMARY  
Strengths**  
- The pragmatic, open design enhances the applicability of the trial findings in daily practice.  
- The pragmatic, open design is most suited to address the key secondary outcomes of the impact of the analgesic ear drops on the proportion of children consuming antibiotics and its cost-effectiveness in

everyday practice.  **Limitations**- The combination of the open design and the subjective, parent-reported outcomes does not control for the placebo effects, but will more closely reflect the benefits that would accrue in everyday practice with regard to analgesic effects.  
- Contamination is possible given the over-the-counter availability of analgesic eardrops.

**INTRODUCTION**Although the current COVID-19 pandemic has a profound influence on the incidence of acute otitis media (AOM) in children1-3, it will remain an important cause of primary care consultations.4 5 Ear pain is the predominant symptom and central to children’s and parents’ experience of the condition.6 7 High-quality studies have shown that most symptoms of AOM settle within a few days without antibiotics in otherwise healthy children living in high-income countries8, but it may take eight days for ear pain to fully resolve in 90% of the children.9 Globally, most AOM clinical practice guidelines therefore recommend oral analgesics in all, and antibiotics in selected, children.10 However, antibiotics are frequently prescribed in children with AOM4 5 leading to side effects in at least 1 out of 10 children and emergence of antimicrobial resistance.11 12 Evidence of effectiveness of management options to relieve the most distressing symptom of AOM and reduce reliance on antibiotics is therefore urgently needed.13

Recently, we found that a general practitioner (GP)-targeted educational intervention to improve pain management in children with AOM resulted in an increase in oral analgesic use, in particular ibuprofen, but failed to reduce parent-reported ear pain and antibiotic use.14 Therefore, alternative interventions need further exploration. Analgesic ear drops, widely available, cheap and safe, may be well-suited to fill this gap. When applied into the external auditory canal, these agents could relieve pain and distress by blocking nerve conduction of the tympanic membrane.15 So far, evidence on their use in children with AOM is limited.15 16 Our trial aims to produce this important evidence.

**OBJECTIVE**The primary aim of this pragmatic randomised controlled trial is to investigate whether analgesic ear drops added to usual care (oral analgesics with/without antibiotics) provide superior ear pain relief over usual care alone in children presenting to primary care with AOM and ear pain.

**METHODS AND ANALYSIS  
Study design and setting**A pragmatic, two arm, individually randomised, open, superiority trial with cost-effectiveness analysis in general practices in the Netherlands with a follow-up of 4 weeks will be performed. Potential trial participants will be recruited from primary care (approximately from 150 GPs) in the region of Utrecht, The Netherlands.

A mixed-method process evaluation will be nested within the trial (see Supplemental Material 1).17-22 This process evaluation will capture data to understand how participating in the trial has an impact on the consultation and behaviour and how AOM interventions (including analgesic ear drops, antibiotics and oral analgesics) are viewed by parents and GPs. The process evaluation consists of a survey with brief statements measuring attitudes of all parents based on the extended Common Sense Model17 and a three-item Consultation Satisfaction Questionnaire,18 and a qualitative part (semi-structured interviews capturing parents and GP’s views and experiences, respectively).  
  
**Participants**Children aged 1-6 years presenting to primary care with AOM23 and parent-reported ear pain in 24 hours prior to enrolment will be eligible for trial participation. Children with (suspected) tympanic membrane perforation or ventilation tube (as they carry a risk of inner ear damage causing hearing loss or tinnitus after application of lidocaine drops), ear wax obscuring visualisation of the tympanic membrane or those who are very unwell or require hospitalisation will be excluded. Detailed inclusion and exclusion criteria are listed in Box 1.   
 **Box 1. Full list of inclusion and exclusion criteria**

**Inclusion criteria:**   
- Age 1 to 6 years  
- Parent-reported ear pain in 24 hours prior to enrolment  
- GP-diagnosis of (uni- or bilateral) AOM  
  
**Exclusion criteria:**  
Children:  
- with (suspected) tympanic membrane perforation or ventilation tubes   
- with ear wax obscuring visualisation of the tympanic membrane   
- who are systemically very unwell or require hospital admission (e.g. child has signs and symptoms of serious illness and/or complications such as mastoiditis/meningitis)  
- who are at high risk of serious complications including children with known immunodeficiency other than partial IgA or IgG2 deficiencies, craniofacial malformation including cleft palate, Down syndrome and previous ear surgery (with the exception of ventilation tubes in the past)  
- who have a known allergy or sensitivity to study medication or similar substances (e.g. other amide-type anaesthetics: bupivacaine, mepivacaine, prilocaine, etc)   
- who have taken part in any research involving medicines within the last 90 days, or any other AOM-related research within the last 30 days  
- who suffer from chronic recurrent pain of another origin than the ear  
- who have participated in this trial during prior AOM episode

**Study procedures and data collection***Recruitment and inclusion of participants*

Figure 1 depicts a flow diagram of the study procedures. During regular primary care consultations, participating GPs will inform parents of potentially eligible children about the trial. Next, GPs will ask parents who are interested in participation for consent to provide their contact details to the study team at the University Medical Center (UMC) Utrecht. Members of the team will contact the parents by phone the same day to provide detailed information about the trial. If parents provisionally agree to participate and if the child fulfils the trial eligibility criteria, the study physician will visit the child at home. At this home visit, written informed consent for participation in the trial and the semi-structured interview will be obtained (Supplemental Material 2), baseline demographic and disease-specific data will be collected and a physical examination including otoscopy will be performed. Parents are also asked to complete a generic and disease-specific quality of life questionnaires on behalf of their child. A full description of the nested process evaluation is given in Supplemental Material 1

*Study group assignment*  
At the conclusion of the home visit, a trial randomisation website will be accessed for concealed study-group assignment. An independent data manager generates a computer-generated randomisation sequence stratified for age (<2 years vs 2 years and above), AOM laterality (unilateral vs bilateral), and AOM baseline antibiotic prescribing (yes vs no). Children will be randomly allocated to either 1) lidocaine hydrochloride 5mg/g (Otalgan) ear drops 1-2 drops up to six times daily for a maximum of 7 days24 25 with usual care (oral analgesics, with/without antibiotics) or 2) usual care. Analgesic eardrops will be provided by the study team. These drops should not be used in children with a tympanic membrane perforation or ventilation tube as they carry a risk of inner ear damage causing hearing loss or tinnitus. These children will therefore be excluded, as well as those with ear wax obscuring visualisation of the tympanic membrane. Parents of children allocated to the intervention group are expressly instructed to stop applying the drops if their child develops ear discharge.

The study team will notify the GP about the result of the randomisation. The local pharmacist will be notified in case the child is allocated to the analgesic ear drops, in order to check any known sensitivities/allergies and any interactions (with current or future drugs). Any treatment decisions other than the use of analgesic ear drops, i.e. antibiotics and oral analgesics, will be left to the GP’s discretion in both groups. To those allocated to the intervention group, the study physician will not provide any treatment advice other than instructions about the use of analgesic ear drops. To those allocated to the control group, the study physician will not provide any treatment advice.

During follow-up parents and GPs will be encouraged to manage AOM symptoms according to current clinical practice guidance on AOM in children issued by the Dutch College of General Practitioners. Lidocaine eardrops are currently not recommended in this guideline due to the lack of evidence.23

*Follow-up data collection*   
Participants will be followed for 4 weeks. A telephone call will be scheduled at day 3 which will allow us to capture critical data on our primary outcome. Parents will keep a diary of AOM-related symptoms including ear pain scores and fever recordings, treatment adherence, prescribed and over-the-counter (OTC) medication use, AOM-related health care resource use, child care and travel costs, adverse events and complications of AOM for 4 weeks. At the end of follow-up, parents will complete a questionnaire on parental productivity losses and generic and disease-specific quality of life questionnaires. The diary and questionnaires can either be completed online or on paper forms (see data management). The study team will contact the parents by phone to check if all data is collected. During this phone call, an appointment for the semi-structured interview can be made with parents who are still willing to participate in the nested qualitative investigation.  
  
*Validated questionnaires used in the trial*  
- Child’s ear pain intensity will be reported by parents in the symptom diary using a 0-10 numerical rating scale which has been validated for measuring pain in children with AOM.26  
- Child’s symptoms of crying/distress, disturbed sleep, interference with normal activity, appetite, fever and hearing problems will be reported by parents in the symptom diary using a 0-6 Likert scale with higher scores indicating greater severity. This scale has been proven valid and was successfully used in our previous trials.16 26  
- Generic quality of life of the child at baseline and 4 weeks will be assessed using the 47-item short-form of the Infant Toddler Quality of Life Questionnaire (ITQOL-SF47) which is developed for use in infants and toddlers aged 2 months to 6 years and has shown to be a feasible instrument with adequate psychometric properties to discriminate between children with and without doctor-diagnosed respiratory disease.27  
- Disease-specific quality of life of the child at baseline and 4 weeks will be assessed using the Otitis media-6 (OM-6) questionnaire.28  
- Productivity losses (e.g. parental absenteeism from work) because of AOM of their child will be assessed using the IMTA Productivity Cost Questionnaire (iPCQ) at 4 weeks.29

**Outcomes***Primary outcome*  
The parent-reported ear pain score over the first three days. To this end, parents will record their child’s ear pain scores during the first three consecutive days using a 0-10 validated numerical rating scale.  
  
*Secondary outcomes*  
- proportion of children consuming antibiotics in the first 7 days;  
- oral analgesic use in the first 7 days;  
- overall symptom burden (crying/distress, disturbed sleep, interference with normal activity, appetite,

fever and hearing problems) using a 0-6 Likert scale in the first 7 days;  
- number of days with ear pain during follow up (4 weeks);  
- number of GP reconsultations with/without subsequent antibiotic prescribing during follow-up;  
- adverse events during follow-up;  
- complications of AOM during follow-up;  
- costs and cost-effectiveness during follow-up;  
- generic quality of life of the child at 4 weeks;  
- disease-specific quality of life of the child at 4 weeks;  
- parents’ and GPs’ views of treatment acceptability, usability and satisfaction.

**Sample size calculation**The main aim is to demonstrate that analgesic ear drops as added to usual care provide superior parent-reported ear pain relief over the first three days compared to usual care. In our recent trial, the mean parent-reported ear pain score (0-10 scale) over the first three days was 4.36 (SD 2.12) among those allocated to usual care.14 Patient and Public Involvement (PPI) input from the UK suggested that a 1-point reduction (on a 0-10 scale) would be a clinically important difference.16 However, our parent panel felt that even a somewhat smaller difference would be clinically meaningful given the low cost, low risk nature of the intervention. To detect a pain reduction of 20% (reflecting a 0.87 point reduction in pain) compared with usual care with 90% power (beta 0.1) and at a 5% significance level (alpha 0.05), 126 children per group will be needed. To allow for 20% attrition, we aim to include 300 participants.

The estimated sample size will also provide substantial power to address the key secondary outcome of the proportion of children consuming antibiotics. Anticipating 47% of children consuming antibiotics in the usual care group as with our previous trial14, 252 children will provide 89% power (beta 0.11; alpha 0.05) to detect a 20% difference in the proportion of children consuming antibiotics.  
  
**Data management**  
During study conduct, we will comply with the EU General Data Protection Regulation and the Dutch Act on Implementation of the General Data Protection Regulation. The data management department of the Julius Center, UMC Utrecht will be responsible for handling and storage of the trial data using a secured and coded online database (Research Online 2.0 [RO 2.0]). Data will be either entered directly into RO 2.0 or collected on paper forms first. For data entered directly into RO 2.0, processes to promote data quality are added. Coded trial data will be securely stored for 25 years in the main study folder on a central drive of the Julius Center.

**Patient and public involvement**A panel of eight parents was established for this trial. This panel helped to shape the grant proposal and final study protocol during online focus group meetings, with particular advice given on patient-relevant outcomes including the minimally important clinical differences, recruitment strategy, and the design of data collection. The parent panel will be actively involved throughout all critical stages of the trial through regular parent panel meetings.

**Statistical analysis**  
All analyses will be performed according to the intention-to-treat (ITT) principle and blinded with respect to study-group assignment. The results will be reported in accordance with the CONSORT guidelines.30

*Clinical effectiveness*   
Descriptive statistics will be used to assess any baseline differences between treatment groups. The primary outcome will be analysed with a linear regression model with a residual covariance (i.e. GEE type) matrix to correct for repeated measurements. In main (adjusted) analysis, treatment group, time, a priori specified prognostic factors (baseline ear pain score, duration of ear pain prior to enrolment) and stratification factors (age (<2 years vs 2 years and above), AOM laterality (unilateral vs bilateral), and baseline antibiotic prescribing (yes vs no)) will be included in the model. The validity of the model, i.e. normality and homoscedasticity, will be evaluated by assessing residuals and the comparison between treatment groups will be expressed as differences in means with 95% confidence intervals (CIs). If more than 5% of baseline and outcome data is missing, a sensitivity analysis will be performed using multiple imputation techniques.31 32

Secondary outcomes will be analysed using negative-binomial regression analyses for count variables, log binomial regression analyses for dichotomous variables, and linear regression analyses for continuous variables, where applicable adjusted for repeated measurements. For these analyses, the comparison between treatment groups will be expressed as rate ratios, risk ratios, and mean differences, respectively; all with 95% CIs.

We will also conduct pre-specified, exploratory subgroup analyses to investigate whether age (<2 years vs 2 years and above) or AOM laterality (unilateral vs bilateral) modify the effectiveness of analgesic ear drops. In further sensitivity analysis, we will also explore the added impact of antibiotic consumption on the primary outcome of interest.  
  
*Cost effectiveness analysis*  
Alongside the trial, a cost effectiveness analysis from a societal perspective, i.e. including both medical and non-medical costs, will be performed. The societal perspective is particularly relevant in this case, since non-medical costs are particularly relevant in AOM.33 Those costs mainly relate to parental productivity losses and costs of additional childcare.  
  
Costs analysis  
All costs will be estimated at the patient level. Costs of medication use will be retrieved from the Dutch formulary and a pharmacist’s fee will be added for every prescription.24 34 Costs of OTC and complementary medicines will be calculated per day, based on current average retail prices. Costs of consulting a GP or a medical specialist, and costs of hospitalisations will be based on current Dutch guidelines for pharmaco-economic evaluation in health care research. Costs of diagnostic tests will also be derived from these guidelines.34 35 Costs of surgical procedures will be retrieved from a previous Dutch costing study that calculated costs for the different components of surgical procedures.36

Resource use such as doctor’s visits, prescribed medication (including antibiotics), specialist referrals, hospital admissions, surgical interventions as well as out-of-pocket expenses such as OTC medication, child care, and travel costs will be collected from study diaries filled out by parents. Cost prices will be estimated according to guidelines for pharmaco-economic evaluation in health care research.34 35 Costs associated with productivity losses will be retrieved from the iPCQ questionnaire and estimated using the friction cost method.29 37 The hourly cost estimate for childcare will be derived from the Dutch National Institute for Family Finance Information (NIBUD).38 Travel expenses will be calculated for healthcare visits following the Dutch guideline for economic evaluation.35 Mean costs per patient will be compared across the randomisation groups.. As the time horizon is only 4 weeks, discounting does not apply.  
  
Cost-effectiveness results  
Costs from a societal perspective will be compared with the parent-reported ear pain scores over the first three days. We will calculate incremental cost-effectiveness ratios by dividing the estimated differences in costs between groups by the differences in effects observed, i.e. the additional cost per additional 1 point reduction in mean ear pain score over the first three days for the analgesic ear drops group versus the usual care group. Uncertainty will be addressed by means of two-stage non-parametric bootstrap sampling. The effect of any difference in baseline characteristics on cost-effectiveness results will be investigated using net benefit regression methods. In case of missing data, we will use multiple imputation techniques. The final results will be presented using incremental cost-effectiveness planes and cost-effectiveness acceptability curves.  
 **Monitoring and safety**The trial will be monitored regularly by an independent research data monitor of the UMC Utrecht to ensure the quality of the trial execution. Since we do not expect any safety issues and the overall risk of this trial was judged negligible, we have not established a data safety monitoring board and refrain from conducting a safety interim analysis. However, in accordance to section 10, subsection 4, of the WMO, the sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. **ETHICS AND DISSIMINATION**The study will be conducted according to the principles of the Declaration of Helsinki (10th version, October 2013), the ICH GCP E6(R2) guideline, the Dutch Law on medicinal products (‘geneesmiddelenwet’) and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical Research Ethics Committee Utrecht, the Netherlands, has approved the protocol (21-447/G-D).

Research findings will be disseminated through publications in peer reviewed medical journals targeted towards the wider audience of health professionals involved in the care of children and presented at relevant national and international scientific meetings. We will work with our parent panel to help interpret the findings of the trial and harness their resources for dissemination to the lay public.  
On completion of the trial, data will be stored for a minimum of 25 years at a central data drive at the Julius Center. We will publish the metadata in the DataverseNL repository and will provide a persistent identifier. The data will be available to researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals to gain access to the data should be directed to the principle investigator (RPV). Data requestors will need to sign a data sharing agreement.  
 **CURRENT STUDY STATUS**Study enrolment is ongoing with the first participant being included on 6 October 2021.  
 **DISCUSSION**Up to now, evidence on the use of analgesic ear drops in children with AOM is limited. A 2011 systematic review included five studies of which two (117 children) compared analgesic ear drops to placebo.15 The authors concluded that these trials provide limited evidence that a single dose of analgesic ear drops is effective in reducing ear pain 30 minutes after administration in older children (age 3 to 19 years) with AOM.15 Since then, a UK-based trial compared at-home, repeated dosing, of analgesic ear drops with placebo ear drops and usual care. This trial was terminated prematurely due to operational issues.16 Initial data of 84 children recruited in primary care indicate that ear pain levels were lower in both ear drops groups than in the usual care group. However, these estimated treatment effects are imprecise because of the low sample size target and therefore require confirmation in future studies.

Our trial aims to do so by assessing the clinical and cost effectiveness of analgesic eardrops in children with AOM, as well as views and experiences of parents and GPs through the nested process evaluation. The pragmatic, open design enhances the applicability of the trial findings to daily practice and is most suited to address the key secondary outcome of the impact of the analgesic ear drops on the proportion of children consuming antibiotics in everyday practice.39 This would be much more difficult to determine realistically in a placebo-blinded study where children in both groups would receive ear drops (either placebo or analgesic drops); such ‘treatment’ may in itself lead to altered parental (health care seeking) behaviour. Additionally, the open design, in which the control group receives usual care, is most suited for ‘real world’ cost-effectiveness analysis. However, the lack of blinding in combination with the subjective, parent-reported outcomes might also lead to bias in the assessment of analgesic effects. To minimise this potential bias, the study physician will emphasize during the baseline visit that it is not known whether the drops have any effect in children with AOM. Furthermore, a recent meta-epidemiological study found no evidence for a difference in estimated treatment effect between blinded and non-blinded trials.40 Although it is still unclear what caused the results of this study, it suggests that blinding is less important than anticipated. Our design does not control for the placebo effects, but will more closely reflect the benefits that would accrue in everyday practice with regard to analgesic effects.

Albeit not recommended in the Dutch AOM clinical practice guideline23, the OTC availability of lidocaine eardrops may inherently incur the risk of contamination, i.e. parents in the control group buying lidocaine ear drops themselves. We consider this unlikely since only 5% (10/221) of participants did use lidocaine ear drops in our previous trial of a GP-targeted educational intervention to improve pain management in

children with AOM.14 We will, however, capture data on the use of lidocaine ear drops in all trial participants to monitor potential contamination.

**ACKNOWLEDGEMENTS**   
We gratefully thank our parent panel for their valuable input and all children and parents who participated in our trial thus far.  
**AUTHOR’S CONTRIBUTIONS**

RPV, AGMS and RAMJD designed the trial. JLHdS, SH and RPV drafted the first version of the protocol paper. All other authors (RAMJD, AGMS, EAMS, GAdW, NPAZ, LY, SA, PL and ADH) provided feedback on this version. All authors (JLHdS, SH, RPV, RAMJD, AGMS, EAMS, GAdW, NPAZ, LY, SA, PL and ADH) approved the final version of the manuscript.  
**FUNDING STATEMENT**The trial is supported by a grant from the Netherlands Organisation for Health Research and Development (ZonMw– grant number 10060011910003). The funding agency had no role in the design, and will not have any role during execution of the trial, data-analyses, interpretation of the data or decision to submit results. LY is an NIHR Senior Investigator and her research programme is partly supported by NIHR Applied Research Collaboration (ARC)-West, NIHR Health Protection Research Unit (HPRU) for Behavioural Science and Evaluation, and the NIHR Southampton Biomedical Research Centre (BRC). **COMPETING INTERESTS**The authors declare that they have no conflict of interest.

**REFERENCES**

1. Hullegie S, Schilder AGM, Marchisio P, et al. A Strong Decline in the Incidence of Childhood Otitis Media During the COVID-19 Pandemic in the Netherlands. *Front Cell Infect Microbiol* 2021;11:768377. doi: 10.3389/fcimb.2021.768377 [published Online First: 2021/11/19]

2. Kaur R, Schulz S, Fuji N, et al. COVID-19 Pandemic Impact on Respiratory Infectious Diseases in Primary Care Practice in Children. *Front Pediatr* 2021;9:722483. doi: 10.3389/fped.2021.722483 [published Online First: 2021/10/01]

3. McBride JA, Eickhoff J, Wald ER. Impact of COVID-19 Quarantine and School Cancelation on Other Common Infectious Diseases. *Pediatr Infect Dis J* 2020;39(12):e449-e52. doi: 10.1097/inf.0000000000002883 [published Online First: 2020/10/09]

4. Gulliford M, Latinovic R, Charlton J, et al. Selective decrease in consultations and antibiotic prescribing for acute respiratory tract infections in UK primary care up to 2006. *J Public Health (Oxf)* 2009;31(4):512-20. doi: 10.1093/pubmed/fdp081 [published Online First: 2009/09/08]

5. van den Broek d'Obrenan J, Verheij TJ, Numans ME, et al. Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment. *J Antimicrob Chemother* 2014;69(6):1701-7. doi: 10.1093/jac/dku005 [published Online First: 2014/02/11]

6. Barber C, Ille S, Vergison A, et al. Acute otitis media in young children - what do parents say? *Int J Pediatr Otorhinolaryngol* 2014;78(2):300-6. doi: 10.1016/j.ijporl.2013.11.030 [published Online First: 2014/01/01]

7. Hansen MP, Howlett J, Del Mar C, et al. Parents' beliefs and knowledge about the management of acute otitis media: a qualitative study. *BMC Fam Pract* 2015;16:82. doi: 10.1186/s12875-015-0297-7 [published Online First: 2015/07/08]

8. Venekamp RP, Sanders SL, Glasziou PP, et al. Antibiotics for acute otitis media in children. *Cochrane Database Syst Rev* 2015(6):CD000219. doi: 10.1002/14651858.CD000219.pub4 [published Online First: 2015/06/24]

9. Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. *BMJ* 2013;347:f7027. doi: 10.1136/bmj.f7027 [published Online First: 2013/12/18]

10. Ovnat Tamir S, Shemesh S, Oron Y, et al. Acute otitis media guidelines in selected developed and developing countries: uniformity and diversity. *Arch Dis Child* 2017;102(5):450-57. doi: 10.1136/archdischild-2016-310729 [published Online First: 2016/09/08]

11. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *Bmj* 2010;340:c2096. doi: 10.1136/bmj.c2096 [published Online First: 2010/05/21]

12. Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. *Cmaj* 2015;187(1):E21-e31. doi: 10.1503/cmaj.140848 [published Online First: 2014/11/19]

13. Pouwels KB, Dolk FCK, Smith DRM, et al. Actual versus 'ideal' antibiotic prescribing for common conditions in English primary care. *J Antimicrob Chemother* 2018;73(suppl\_2):19-26. doi: 10.1093/jac/dkx502 [published Online First: 2018/03/01]

14. van Uum RT, Venekamp RP, Zuithoff NP, et al. Improving pain management in childhood acute otitis media in general practice: a cluster randomised controlled trial of a GP-targeted educational intervention. *Br J Gen Pract* 2020;70(699):e684-e95. doi: 10.3399/bjgp20X712589 [published Online First: 2020/08/26]

15. Foxlee R, Johansson A, Wejfalk J, et al. Topical analgesia for acute otitis media. *Cochrane Database Syst Rev* 2006(3):Cd005657. doi: 10.1002/14651858.CD005657.pub2 [published Online First: 2006/07/21]

16. Hay AD, Downing H, Francis NA, et al. Anaesthetic-analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT. *Health Technol Assess* 2019;23(34):1-48. doi: 10.3310/hta23340 [published Online First: 2019/07/16]

17. Horne R. Treatment perceptions and self-regulation. In: Leventhal H, Cameron L, eds. The self-regulation of health and illness behaviour. London: Routledge 2003:138–53.

18. Yardley L, Douglas E, Anthierens S, et al. Evaluation of a web-based intervention to reduce antibiotic prescribing for LRTI in six European countries: quantitative process analysis of the GRACE/INTRO randomised controlled trial. *Implement Sci* 2013;8:134. doi: 10.1186/1748-5908-8-134 [published Online First: 2013/11/19]

19. van Uum RT, Sjoukes A, Venekamp RP, et al. Pain management in acute otitis media: a qualitative study exploring GPs' views and expectations parallel to a trial of an educational intervention. *BJGP Open* 2018;2(4):bjgpopen18X101620. doi: 10.3399/bjgpopen18X101620 [published Online First: 2019/02/07]

20. van Uum RT, Venekamp RP, Schilder AGM, et al. Pain management in acute otitis media: a qualitative study of parents' views and expectations. *BMC Fam Pract* 2019;20(1):18. doi: 10.1186/s12875-019-0908-9 [published Online First: 2019/01/25]

21. Braun V, Clarke V. What can "thematic analysis" offer health and wellbeing researchers? *Int J Qual Stud Health Well-being* 2014;9:26152. doi: 10.3402/qhw.v9.26152 [published Online First: 2014/10/19]

22. Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol* 2013;13:117. doi: 10.1186/1471-2288-13-117 [published Online First: 2013/09/21]

23. Damoiseaux RAMJ, Venekamp RP, Eekhof J. NHG-standaard OMA bij kinderen (derde herziening). *Huisarts Wet* 2014;57:648.

24. Farmacotherapeutisch Kompas [Available from: <https://www.farmacotherapeutischkompas.nl/>.

25. Dutch Children's Formulary 'Kinderformularium' [Available from: <https://www.kinderformularium.nl/>.

26. Little P, Gould C, Williamson I, et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. *Bmj* 2001;322(7282):336-42. doi: 10.1136/bmj.322.7282.336 [published Online First: 2001/02/13]

27. Raat H, Landgraf JM, Oostenbrink R, et al. Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. *Qual Life Res* 2007;16(3):445-60. doi: 10.1007/s11136-006-9134-8 [published Online First: 2006/11/18]

28. Rosenfeld RM, Goldsmith AJ, Tetlus L, et al. Quality of life for children with otitis media. *Arch Otolaryngol Head Neck Surg* 1997;123(10):1049-54. doi: 10.1001/archotol.1997.01900100019002 [published Online First: 1997/10/27]

29. Bouwmans C, Krol M, Brouwer W, et al. IMTA Productivity Cost Questionnaire (IPCQ). *Value Health* 2014;17(7):A550. doi: 10.1016/j.jval.2014.08.1791 [published Online First: 2014/11/01]

30. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Bmj* 2010;340:c332. doi: 10.1136/bmj.c332 [published Online First: 2010/03/25]

31. Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle introduction to imputation of missing values. *J Clin Epidemiol* 2006;59(10):1087-91. doi: 10.1016/j.jclinepi.2006.01.014 [published Online First: 2006/09/19]

32. Rubin D. Multiple imputation for non-response in surveys. New York: John Wiley 1987.

33. Wolleswinkel-van den Bosch JH, Stolk EA, Francois M, et al. The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. *Vaccine* 2010;28 Suppl 6:G39-52. doi: 10.1016/j.vaccine.2010.06.014 [published Online First: 2010/11/16]

34. Zorginstituut Nederland. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 2016 ed. Diemen: Zorginstituut Nederland 2016.

35. Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland 2016.

36. Buskens E, van Staaij B, van den Akker J, et al. Adenotonsillectomy or watchful waiting in patients with mild to moderate symptoms of throat infections or adenotonsillar hypertrophy: a randomized comparison of costs and effects. *Arch Otolaryngol Head Neck Surg* 2007;133(11):1083-8. doi: 10.1001/archotol.133.11.1083 [published Online First: 2007/11/21]

37. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. *J Health Econ* 1995;14(2):171-89. doi: 10.1016/0167-6296(94)00044-5 [published Online First: 1995/05/08]

38. National Institute for Family Finance Information website [Available from: <https://www.nibud.nl/consumenten/kosten-van-kinderopvang/>.

39. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. *Trials* 2009;10:37. doi: 10.1186/1745-6215-10-37 [published Online First: 2009/06/06]

40. Moustgaard H, Clayton GL, Jones HE, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. *Bmj* 2020;368:l6802. doi: 10.1136/bmj.l6802 [published Online First: 2020/01/23]

**Figure 1. Flow diagram of study procedures**

Legend: *AOM: acute otitis media, GP: general practitioner, OPTIMA: trial acronym  
 \** Parents who gave consent for the semi-structured interview will be recruited from both the intervention and control arm and will be purposively sampled after follow-up.

**Supplemental material****1. Methods and analyses mixed-method process evaluation  
Supplemental material 2. Informed consent form**